Board of Directors
News & Events
The Path to Personalized Treatment
For the past 15 years, we have built a highly curated biorepository containing more than 200,000 samples derived from over 20,000 patients.
Samples are linked with extensive clinical and research metadata, including genotypic, phenotypic, transcriptomic, endoscopic, histologic and MRI data to create the most advanced dataset in IBD of its kind.
Utilizing advanced data mining and machine-learning analysis approaches, the dominant disease biology in subgroups of IBD patients is deciphered.
Prometheus Biosciences uses these dominant disease pathways and associations to design new drugs for specific patient groups.
Companion diagnostic tests are developed to predict response to these new therapies, providing the right drug for the right patient.